Last reviewed · How we verify
VNX001
At a glance
| Generic name | VNX001 |
|---|---|
| Also known as | Alkalinized lidocaine HCl and heparin sodium |
| Sponsor | Vaneltix Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) (PHASE2)
- Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VNX001 CI brief — competitive landscape report
- VNX001 updates RSS · CI watch RSS
- Vaneltix Pharma, Inc. portfolio CI